New first-line treatment option for metastatic prostate cancer
Full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate
The FDA has approved Talzenna (talazoparib) with Xtandi (enzalutamide) as first-line treatments for some patients with metastatic castration-resistant prostate cancer. (Posted 10/2/23)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Should I have genetic testing for a mutation in genes linked to prostate cancer?
- Should I have tumor testing?
- Is Talzenna or another PARP inhibitor an option for me?
- Will my health insurance pay for Talzenna?
Open Clinical Trials
The following resources focus on prostate cancer.
- FORCE prostate cancer resources:
- Malecare has extensive resources for people with prostate cancer.
- National Comprehensive Cancer Network free patient guides:
The National Comprehensive Cancer Network guidelines recommend genetic counseling and testing for the following people with prostate cancer who have:
- a tumor test result that suggests an inherited mutation
- for example, a tumor with a BRCA1, BRCA2 or ATM mutation may indicate an inherited mutation in one of those genes
- a blood relative who tested positive for an inherited mutation in a gene linked to prostate cancer
- metastatic prostate cancer diagnosed at any age
- prostate cancer that has spread to the lymph nodes
- localized prostate cancer (hasn’t spread beyond the prostate) that is considered very high-risk or high-risk
- intermediate-risk prostate cancer with intraductal or cribriform features listed on the pathology report
- a diagnosis of male breast cancer
- Eastern European (Ashkenazi) Jewish ancestry
- one or more relatives with:
- breast, colorectal or endometrial cancer diagnosed at age 50 or younger
- male breast cancer, triple negative breast cancer, ovarian cancer or pancreatic cancer at any age
- metastatic, regional, very-high-risk, or high-risk prostate cancer at any age
- one or more close relatives with prostate cancer diagnosed at age 60 or younger
- three or more relatives on the same side of the family with biliary tract, breast, colorectal, endometrial, glioblastoma, prostate or other cancers
Speak with a genetic counselor if you have questions about whether you meet guidelines for genetic testing.
The following studies are looking at PARP inhibitors and similar agents for treating people with advanced prostate cancer.
Other clinical trials for people with prostate cancer can be found here.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.